Kohl's adopts 'poison pill', says buyout offers undervalue it
Reuters
Published Feb 04, 2022 08:39AM ET
Updated Feb 04, 2022 02:05PM ET
(Reuters) -Kohl's Corp on Friday adopted a shareholder rights plans to protect itself from hostile takeovers, days after receiving buyout offers that the retailer said undervalued it.
Last month, activist investor Starboard Value-backed Acacia Research Corp offered to buy the department-store chain for $64 a share, valuing it at roughly $9 billion.
Around the same time, sources told Reuters that Sycamore Partners was also preparing an all-cash offer for Kohl's (NYSE:KSS) at $65 per share.
Without naming its suitors, Kohl's said on Thursday the offers did not adequately reflect its future growth and cash flow generation. It has hired Goldman Sachs (NYSE:GS) to engage in talks with interested parties about a potential sale.
Activist investors Macellum Advisors and Engine Capital, unhappy with Kohl's performance, have been pressuring it to explore options including a sale.
Macellum, which owns nearly 5% of Kohl's stock, said it was "disappointed and shocked" by the company's decision. It added that the board is taking "unprecedented" steps to douse growing takeover interest.
Shares of the company rose 1%, adding on to a 25% gain over the past two weeks on news of the offers. It had a market value of $8.15 billion as of Thursday's close, according to Refinitiv.
Morningstar analysts said it is "risky" to reject credible offers, especially after unfavorable market conditions for Kohl's in 2021.
Sycamore declined to comment and Acacia did not respond to a request for comment.
The company also said the shareholder rights plan, popularly known as a "poison pill", expires in February 2023. The rights will be exercisable if a person or group, other than passive institutional investors, acquires a stake of 10% or more.
Poison pills make a proposed takeover more expensive or difficult by allowing existing shareholders to buy additional shares at a discount, diluting a hostile suitor's ownership stake.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.